Our store location is now open with huge sales on RUO products. Monday, Wednesday and Friday 11 a.m. to 6 p.m., Saturday 11 a.m. to 4 p.m.
Marvel Peptide USA
ARA-290

ARA-290

Supplied as a lyophilized powder in a sealed vial, for laboratory research use only.

$25.00 per vial

Strengths and prices

StrengthPrice per vial AvailabilityBatch
10 mg $25.00 In stock —

Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.

What it is

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide modeled on the helix B surface of erythropoietin. It was designed to act at the innate repair receptor without the blood-forming activity of erythropoietin.

Identity

TypeSynthetic peptide, 11 amino acids
Molecular formulaC51H84N16O21
Molecular weight1257.3 g/mol
CAS number1208243-50-8
PubChem CID91810664

ARA-290 (cibinetide) is a synthetic linear peptide of 11 amino acids, pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, modeled on the aqueous face of helix B of erythropoietin, and is also called pyroglutamate helix B surface peptide. The N-terminal residue is pyroglutamate, a glutamine cyclized onto its own side chain, so the peptide has no free N-terminal amine; the C-terminus is a free acid. Molecular formula C51H84N16O21, molecular weight 1257.3 g/mol (PubChem CID 91810664, CAS 1208243-50-8). It contains no cysteine. Mass spectrometry confirms the mass, which distinguishes the cyclized peptide from the open-chain glutamine form, 17 mass units heavier, and HPLC reports purity. It is supplied as a lyophilized powder in a sealed vial.

What the published research covers

Cibinetide has been studied in animal models of nerve injury and in small phase 2 clinical trials in sarcoidosis-associated small fiber neuropathy and in type 2 diabetes.

ARA-290, later given the name cibinetide, was designed by Michael Brines, Anthony Cerami and colleagues in their work on the tissue-protective effects of erythropoietin (EPO). They held that EPO drives red cell production through a homodimer of the EPO receptor but protects tissue through a different receptor, a complex of the EPO receptor with CD131, the beta common receptor. In 2008 they reported that helix B of EPO, and an 11-amino-acid peptide built from the adjacent residues that form its aqueous face, were tissue protective in rodent models of ischemic stroke and renal ischemia-reperfusion, accelerated wound healing, and were not erythropoietic in vitro or in vivo (Brines, 2008).

In rats with a spared nerve injury, the peptide reduced mechanical and cold allodynia for up to 20 weeks compared with vehicle and, at some of the amounts tested, suppressed the spinal microglia response (Swartjes, 2014). The human studies are small. A double-blind pilot trial in 22 patients with sarcoidosis and symptoms of small fiber neuropathy reported a greater improvement over four weeks in a small fiber neuropathy screening score than with placebo, while pain and fatigue scores improved to a similar degree in both groups (Heij, 2012). A phase 2 study in type 2 diabetes with painful neuropathy, 28 days of active study followed by a month without it, reported improvements in hemoglobin A1c, lipid profiles and a neuropathic symptom questionnaire, and an increase in corneal nerve fiber density in participants whose baseline density was more than one standard deviation below normal (Brines, 2015). A 64-subject phase 2b trial in sarcoidosis-associated small nerve fiber loss used the change in corneal nerve fiber area at 28 days as its primary endpoint; the placebo-corrected increase was significant in one of the three active groups, and pain improved significantly in all groups (Culver, 2017).

The trials were short, enrolled tens of participants, and relied partly on patient-reported scores and on corneal nerve measures as surrogate endpoints. Officers of Araim Pharmaceuticals, the company developing the peptide, are among the authors of the clinical papers. Other groups have studied the peptide in animal models, but no phase 3 trial has been published.

Regulatory status

Investigational. Not approved by the FDA for any use. Supplied for laboratory research only.

Testing and documentation

Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.

Questions laboratories ask

What strengths is ARA-290 offered in?
Vials of 10 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
Is ARA-290 the same as cibinetide?
Yes. ARA-290 is the development code and cibinetide the nonproprietary name for the same 11-amino-acid peptide. Cibinetide is investigational: it is not approved by the FDA for any use, and this material is supplied for laboratory research only.
How is a batch tested?
By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
Who can order, and how does it ship?
Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.

References

  1. Brines M et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America. PubMed 18676614
  2. Heij L et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine. PubMed 23168581
  3. Swartjes M et al. (2014). ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular Pain. PubMed 24529189
  4. Brines M et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. PubMed 25387363
  5. Culver DA et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology & Visual Science. PubMed 28475703

How it ships

Next day
Dispatched from Montana on all orders, packed and tracked.
One vial
The minimum order. You pay by card at checkout, or by invoice before the order ships.
Your batch
The certificate of analysis for the batch you receive is on the vial and on this site.

Ordering

Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.

Research use only

This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement

More from the catalog

All peptides, strengths and prices →